In today’s briefing:
- D. Western Therapeutics Institute (4576 JP) – News Flash – Sep 5, 2024
- CYBERDYNE (7779 JP) – Overseas Initiatives Driving Sales and Reducing Losses
- Neuren Pharmaceuticals (NEU AU): Ready to Fly Again After a Breather
- Agilent Technologies: A Tale Of Geographic Diversification and Emerging Market Growth! – Major Drivers
- Ainos, Inc. – Adding Coronavirus Treatment and Prevention to Veldona Patent Portfolio
D. Western Therapeutics Institute (4576 JP) – News Flash – Sep 5, 2024
- DWTI announced that the first transplant was performed in a domestic Phase II clinical study of DWR-2206 (Indication: bullous keratopathy, see Note 1 below), a regenerative medicine cell product being developed jointly by DWTI and ActualEyes Inc., and as a result of the follow-up monitoring, the safety of DWR-2206 has been confirmed in order to proceed to a second and subsequent transplants.
- This study is being conducted to evaluate the safety and efficacy of DWR-2206 transplants in patients with bullous keratopathy.
- The first transplant took place in July 2024, and the patient’s progress since the transplant has been smooth.
CYBERDYNE (7779 JP) – Overseas Initiatives Driving Sales and Reducing Losses
- Q1 FY3/25 results reported 10.5% sales growth YoY and declining operating losses, driven by a combination of treatment service growth in the Americas and cost reduction efforts.
- Operating units of the key HAL Medical Lower Limb Type grew 8.3% YoY to 481 units worldwide, indicating moderate but sustained growth YoY at home and overseas.
- Overseas sales made up 71% of the total, demonstrating the company’s focus on geographic expansion.
Neuren Pharmaceuticals (NEU AU): Ready to Fly Again After a Breather
- Neuren Pharmaceuticals (NEU AU) shares corrected ~14% over the last one month, as Daybue reported disappointing performance in U.S. and partner reduced 2024 revenue guidance for Daybue.
- Muted U.S. performance of Daybue in 1H24 seems to be short-lived and the drug is expected to accelerate in 2H24 and beyond.
- In 2Q24, the rate of new patient starts was 12% higher than the previous quarter and the rate of discontinuations was 46% lower than in the previous quarter.
Agilent Technologies: A Tale Of Geographic Diversification and Emerging Market Growth! – Major Drivers
- Agilent Technologies showed resilience in its Q3 2024 earnings, despite facing challenges with a 4.4% revenue decline and continued pressure in sectors like biopharma.
- The company reported $1.578 billion in revenues and an earnings per share (EPS) of $1.32, surpassing the upper end of its guidance by $0.04.
- This performance highlights robust operational management and strategic agility in an environment where many sectors are facing budget constraints.
Ainos, Inc. – Adding Coronavirus Treatment and Prevention to Veldona Patent Portfolio
- Veldona patent granted in Taiwan for treatment and prevention of coronavirus infection, securing 20 years of patent protection.
- The invention patent covers the method and composition of a Veldona-based therapeutic approach to stimulate the immune system by dosing Veldona through sublingual and/or buccal administration to reduce the risk of symptomatic coronavirus infections.
- Sublingual and/or buccal administration allows Veldona to be rapidly absorbed by the oral mucosa, enabling more effective treatment and better drug compliance.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
